Genentech Cancer Drug May Help Fight MS
By Amanda Janis/Business Editor
Genentech makes Rituxan in Vacaville. (Courtesy photo)
One of the drugs manufactured for commercial use at Genentech's Vacaville facility may have the potential to treat multiple sclerosis.
A study of the nation's top-selling oncology therapeutic, Rituxan, and its effect on relapsing-remitting multiple sclerosis showed positive initial results, announced Genentech and Biogen Idec, co-marketers of the drug in America. Data will continue to be analyzed, and submitted at an upcoming medical meeting, the companies said.
In a prepared statement, Dr. Alfred Sandrock, Biogen's senior vice president of neurology research and development, called the data encouraging. He noted that the companies "look forward to learning more about the potential of Rituxan as a therapy to treat MS."
In addition to relapsing-remitting multiple sclerosis, the drug is being studied as a possible treatment for primary progressive multiple-sclerosis and other autoimmune diseases.
Rituxan was approved by the Food and Drug Administration to treat a specific type of non-Hodgkin's lymphoma in 1997, and given the green light the following year by the European Union. In February, the FDA approved its use for the same indication in combination with CVP or CHOP chemotherapy, or following CVP chemotherapy treatments.
Genentech spokeswoman Caroline Pecquet previously told The Reporter that should new uses for the drug be approved, the company would expect to increase production locally. She noted that the Vacaville facility is a vital component of the biotech giant's manufacturing process.
Development of new uses for existing products is in line with Genentech's "Horizon 2010" strategic plan, goals of which include bringing into development at least 20 new molecules and marketing at least 15 new products or new uses for existing products.
Amanda Janis can be reached at email@example.com.
Tuesday, August 29, 2006
- ► 2007 (799)
- Second C-17 Arrives at Travis
- Borders Group Inc. is opening a 20,000-square-foot...
- Revival at Nut Tree Driven Home
- Billboards Try to Snatch Business Off Freeway
- Magna Promises Money in Dixon Race Track Agreement...
- Genentech Cancer Drug May Help Fight MS
- Sunset on the Water
- Private Ceremony Set to Mark Railroad
- Family Farm Days Draws Bay Area Visitors
- Nut Tree Markets Park Memberships
- Innovation Key to Rekindling the Sciences
- Downtown's Looking Up
- Sport Chalet to Open at Nut Tree
- Open for Business
- Job Growth in Solano Beats Labor Pool Gain
- Nut Tree regains air ambulance
- "Vallejo Crossroads" project, a 25,000 square foot...
- Nutrition Center is Unveiled
- New Facilities for AmCan to be Discussed at Counci...
- UC Davis and some other California universities ha...
- Innovative Approach
- Nut Tree in Bloom
- Forum scheduled
- Vacaville-Dixon Greenbelt to Expand
- Developer's Plans Thrill Vallejo Mayor
- Dixon Smooths Outlook to Finish Repaving Work
- Group: Fairfield Home Among Top 10 Percent in USA
- Lowe's Might Open Vallejo Store
- Local Weather Stations Helping Farmers
- 'Bully' for Jelly Belly!
- New Projects Slated for City
- Touchdown at Travis
- C-17 Casts First Big Shadow at Travis
- Pylon Signs to Spotlight Nut Tree Site
- Red-Carpet Welcome
- County Cities Could Get Influx of Delta Water
- Solano benefits from economic ties with surroundin...
- Genentech Maps Massive Expansion
- Downtown Revitalized
- Vanden Construction Rolls Ahead
- New Medical Offices Open
- Healthy Candy? Sweet!
- Solano Sees No Need for Universal Care
- A Big Day for Travis, Solano
- Vacaville's Acorn Won't Fall Too Far From the Nut ...
- Pilot Buoyed by New Role
- A Special Debut
- Solano County - Once-quiet corridor from Vallejo t...
- This Fine Ol' House
- Head Start Program Among Nation's Best
- Firm licenses UCD diagnostics for autism
- Crucial Report on Dixon Downs
- Sutter opens Vallejo primary care center
- Solano EDC Hosts Golf Tourney
- ▼ August (54)
- ► 2005 (627)
- ► 2004 (125)